The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.
Steady: 0 in the last 7 days
Updated sep 15
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.EMA is reviewing the vaccine application, and Pfizer has secured exclusive commercialization rights.1 source
- Pfizer and Valneva are co-developing a vaccine and planning regulatory submissions to authorities.Sub-event
EMA validates MAA for Pfizer/Valneva collaborative vaccine.1 source
Keep exploring
The entities involved
-
Valneva SE
French vaccine producer
Nothing else this week.
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
- The European Commission negotiated vaccine procurement with Pfizer, while Bulgaria recorded a high fatality rate and the EPPO began investigating alleged wrongdoing by the Commission.
- A trial involving Pfizer CEO Albert Bourla and Bill Gates was held in Leeuwarden, with Peter Stassen speaking in court.
-
European Medicines Agency
highest regulatory authority on medicines in the European Union